Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor and industry conferences in June.

Jefferies 2019 Healthcare Conference

Date: Wednesday, June 5, 2019

Presentation Time: 8:30 a.m. ET

Location: New York, NY

Webcast: http://ir.aegleabio.com/events-and-presentations/upcoming-events

BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

Date: Tuesday, June 25, 2019

Presentation Time: 11:40 a.m. ET

Location: New York, NY

Webcast: http://ir.aegleabio.com/events-and-presentations/upcoming-events

BIO International Convention

Date: Tuesday, June 4, 2019

Presentation Time: 3:15 p.m. ET

Location: Philadelphia, PA

About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active pipeline of other human enzyme-based approaches including programs for both Homocystinuria and Cystinuria. For more information, please visit http://aegleabio.com.

Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
[email protected] 

Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
[email protected] 

You May Also Be Interested In

• Pepe Coin Drops 12% in a September 23 Selloff While Remittix’s BINANCE500 Campaign Builds Momentum
• Hyperliquid Price Prediction: HYPE Trades Near September Highs as Remittix’s BINANCE500 Offer Opens
• Leo Cancer Care Unveils Bold Plans to Improve How Children Experience Radiotherapy, Following World-First Treatments